Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.

被引：23

作者：

Patel, Manish R.

Falchook, Gerald Steven

Wang, Judy Sing-Zan

Imedio, Esteban Rodrigo

Kumar, Sanjeev

Motlagh, Pejvack

Miah, Kowser

Mugundu, Ganesh M.

Jones, Suzanne Fields

Spigel, David R.

Hamilton, Erika Paige

机构：

[1] Florida Canc Specialists, Sarasota, FL USA

[2] Sarah Cannon Res Inst, Sarasota, FL USA

[3] Sarah Cannon Res Inst HealthONE, Denver, CO USA

[4] AstraZeneca, Cambridge, England

[5] AstraZeneca, Quantitat Clin Pharmacol, ECD, IMED Biotech Unit, Boston, MA USA

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Tennessee Oncol, Nashville, TN USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.2562

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2562

引用

页数：2